←
UroToday.com126,923 posts
UroToday.com avatar✓

UroToday.com ✓

@urotoday

Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology

◷ Joined February 2009▧ 43,781 Photos and videos
UroToday.com avatar
UroToday.com@urotoday·3m

Proactive adverse event management for talazoparib plus enzalutamide in metastatic APMS. @CaPsurvivorship @DanaFarber joins @neerajaiims @huntsmancancer to discuss anemia management in the TALAPRO-3 regimen. The trial added talazoparib to enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, achieving 52% rPFS risk reduction. Dr. Morgans recommends an anemia panel at baseline to identify correctable causes before attributing low hemoglobin to treatment. #WatchNow > bit.ly/45AOzWS

Post attachment
UroToday.com avatar
UroToday.com@urotoday·15h

Dose-Intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial Can dose intensification improve PSMA radioligand therapy in #mCRPC? The rationale behind OPTIMAL-PSMA, a randomized phase 2 trial of dose-intensified 177Lu-PSMA. #AuthorCommentary with Sobia Khan, Gemma Sheehan-Dare, and @drlouiseemmett > bit.ly/4dVAxDJ

Post attachment
UroToday.com avatar
UroToday.com@urotoday·17h

Practical management of nonmuscle-invasive #BladderCancer treatment in the clinic. Samantha Steinke, APRN, MSN-FNP, BSN, RN & Brenda Martone, MSN, ANP-BC, AOCNP @NorthwesternMed review practical intravesical BCG administration. Therapy uses a Foley catheter with a two-hour dwell time, administered either at home or in the clinic based on patient preference and travel distance. Common self-limited side effects, such as urinary frequency, urgency, and low-grade fever, generally appear by treatment three or four, with onset delayed until later that day and typically resolving within 48 hours. #WatchNow > bit.ly/3UVFdmp @NUFeinbergMed @LurieCancer #NMIBC

Post attachment
UroToday.com avatar
UroToday.com@urotoday·23h

Quality of life and bladder-directed therapy after perioperative EV-pembrolizumab. @brian_rini @VUMChealth joins @UroDocAsh @utmdanderson to discuss two pivotal quality-of-life abstracts in #BladderCancer! 📊 Key highlights: 🔹 RAD-IO Trial: Standard CRT + perioperative durvalumab in #MIBC showed an 84% DFS rate, mirroring early landmarks from EV-303, EV-304, & NIAGARA. 🔹 KEYNOTE-905 (FACT-G): Neoadjuvant QoL declines were primarily driven by cystectomy rather than systemic therapy. 🔹 Critical Takeaway: QoL assessments often miss patients who drop out due to progression or toxicity, creating inherent survival/tolerance bias. Dr. Rini emphasizes the urgent need for updated PRO tools capturing both perioperative and long-term bladder-specific toxicities. 🎯 #WatchNow > bit.ly/4hZzSnG

2:05
Laura Graham avatar
⟳ UroToday.com retweeted
Laura Graham@LauraGrahamMD·Nov 16

Thanks to @UroToday for the opportunity to discuss our #SITC2026 findings! Combining T-cell engagement with targeted costimulation represents an exciting strategy in #mCRPC. Encouraging early clinical activity, with much more to learn.

Post attachment
UroToday.com avatar
UroToday.com@urotoday·Nov 16

The role of nurses and advanced practice providers in #NMIBC care. Samantha Steinke, APRN, MSN-FNP, BSN, RN joins Brenda Martone, MSN, ANP-BC, AOCNP @NorthwesternMed to discuss #nursing and APP roles across the nonmuscle-invasive #BladderCancer care pathway. Following TURBT and diagnosis, the urology APP coordinates BCG scheduling, distributes treatment handouts, and answers patient questions before the first infusion. #WatchNow to learn more > bit.ly/4cM9URd

Post attachment
Jim Hu avatar
⟳ UroToday.com retweeted
Jim Hu@jimhumd·Nov 16

1/8 🧵 A small prostate. Systematic + MRI-targeted biopsy. Less than 1 mm of GG1 cancer. Decipher 0.17. Eleven months later: GG4 on repeat biopsy, followed by EPE and a positive margin at prostatectomy. Did we miss aggressive cancer—or did it progress this quickly? We are debating whether GG1 should even be called “cancer.” 🧵 @PCF_Science @PCFnews @urotoday @AmericanCancer @AmerUrological nytimes.com/2023/08/30/opini…

Post attachmentPost attachment